Clinical trials recruiting in Bath, United Kingdom

Phase breakdown

Conditions recruiting in Bath, United Kingdom

Recruiting trials in Bath, United Kingdom

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
  NCT07285655 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female)
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
  NCT07230691 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
  NCT06846554 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography
  NCT06386185 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
  NCT07179380 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Exactech Shoulder Post Market Clinical Follow-up Study
  NCT05603728 · Phase: Not specified · Ages: 21 Years and older · Sex: All (male and female)
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
  NCT02823821 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• SEquential Treatment of PSoriasis With Biologics
  NCT07187817 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
  NCT06486883 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
  NCT07318597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
  NCT07166315 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Virtual Reality in Elective Caesarean Births Study (VREC)
  NCT07130084 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female

Common questions

How many clinical trials are recruiting in Bath, United Kingdom?

21 recruiting trials have at least one study site in Bath, United Kingdom.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.